Modality
Vaccine
MOA
C5i
Target
BET
Pathway
RAS/MAPK
CeliacPBC
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
Feb 2019
→ Apr 2029
Phase 2Current
NCT04722042
290 pts·PBC
2023-06→TBD·Completed
NCT05922498
2,972 pts·Celiac
2019-02→2029-04·Completed
3,262 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-04-123.0y awayPh3 Readout· Celiac
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P2/3
Complet…
P2/3
Complet…
Catalysts
Ph3 Readout
2029-04-12 · 3.0y away
Celiac
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04722042 | Phase 2/3 | PBC | Completed | 290 | Biomarker |
| NCT05922498 | Phase 2/3 | Celiac | Completed | 2972 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET | |
| 207-5197 | Samsung Biologics | Approved | BET | |
| ILM-5680 | Illumina | Phase 2 | BET | |
| Mavuratamab | Blueprint Medicines | NDA/BLA | BET | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D |